Skip to content

Study · Animal study (in vivo) · rat · 1990

6 results

[Appearance of parkinsonian syndrome after administration of delta sleep-inducing peptide into the rat substantia nigra].

Kryzhanovskiĭ GN, Shandra AA, Godlevskiĭ LS, Mikhaleva II

Biulleten' eksperimental'noi biologii i meditsiny1 Feb 1990Cited by 3 (Europe PMC)

PMID2337637 (opens in a new tab)DOI10.1007/bf00841645 (opens in a new tab)PepBankPUB-02337637
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Safety outcome

    In rats, bilateral microinjection of DSIP into the substantia nigra provoked hypokinesia and rigidity.

    In plain wordsIn rats, DSIP injected into a movement-control brain area caused slow movement and stiffness.

    Peptide
    Delta sleep-inducing peptide (DSIP)
    Outcome
    IncreaseHypokinesia and rigidity after bilateral intranigral DSIP
    Study

    ratn: not reported in source

    intracerebral microinjection
    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    10.0 nmol · bilateral microinjection into the substantia nigraAs given in this study (rat).

    Source sentences

    Summary
    Bilateral microinjection of delta-sleep-inducing peptide (DSIP) (10.0 nmol) into the substantia nigra provoked hypokinesia and rigidity in rats
  2. 02AnimalAnimal study (in vivo)Safety outcome

    In rats, DSIP at the lower dose into the substantia nigra did not induce hypokinesia and rigidity.

    In plain wordsIn rats, a lower DSIP dose in the same brain area did not cause slow movement or stiffness.

    Peptide
    Delta sleep-inducing peptide (DSIP)
    Outcome
    No significant changeParkinsonian symptoms after DSIP into substantia nigra at the lower dose
    Study

    ratn: not reported in source

    intracerebral microinjection
    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    5.0 nmol · injection into the substantia nigraAs given in this study (rat).

    Source sentences

    Summary
    Injection of DSIP in dose of 5.0 nmol into the substantia nigra or into the nuclei caudati in dose of 10.0 nmol did not induce such symptoms
    1 context sentence
    Summary · context
    Bilateral microinjection of delta-sleep-inducing peptide (DSIP) (10.0 nmol) into the substantia nigra provoked hypokinesia and rigidity in rats
  3. 03AnimalAnimal study (in vivo)Safety outcome

    In rats, DSIP injected into the caudate nuclei did not induce hypokinesia and rigidity.

    In plain wordsIn rats, DSIP injected into another brain area, the caudate nuclei, did not cause slow movement or stiffness.

    Peptide
    Delta sleep-inducing peptide (DSIP)
    Outcome
    No significant changeParkinsonian symptoms after DSIP into caudate nuclei
    Study

    ratn: not reported in source

    intracerebral microinjection
    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    10.0 nmol · injection into the nuclei caudatiAs given in this study (rat).

    Source sentences

    Summary
    Injection of DSIP in dose of 5.0 nmol into the substantia nigra or into the nuclei caudati in dose of 10.0 nmol did not induce such symptoms
    1 context sentence
    Summary · context
    Bilateral microinjection of delta-sleep-inducing peptide (DSIP) (10.0 nmol) into the substantia nigra provoked hypokinesia and rigidity in rats
  4. 04AnimalAnimal study (in vivo)Mechanism

    In rats with DSIP-induced hypokinesia and rigidity, slow-wave activity was enhanced in the caudate nuclei.

    In plain wordsIn rats with DSIP-induced stiffness, brain wave activity in the caudate nuclei was higher.

    Peptide
    Delta sleep-inducing peptide (DSIP)
    Outcome
    IncreaseSlow-wave activity in caudate nuclei
    Study

    ratn: not reported in source

    intracerebral microinjection
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    10.0 nmol · bilateral microinjection into the substantia nigraAs given in this study (rat).

    Source sentences

    Summary
    The enhanced slow-wave activity was recorded in caudate nuclei during hypokinesia and rigidity which demonstrated the formation of the generator of pathologically enhanced excitation (GPEE).
    1 context sentence
    Summary · context
    Bilateral microinjection of delta-sleep-inducing peptide (DSIP) (10.0 nmol) into the substantia nigra provoked hypokinesia and rigidity in rats

Studies that did not test the peptide alone2

In this study, Delta sleep-inducing peptide (DSIP) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Delta sleep-inducing peptide (DSIP).

  1. 05AnimalNot a test of Delta sleep-inducing peptide (DSIP) aloneAnimal study (in vivo)Efficacy outcome

    In rats with DSIP-induced parkinsonism, systemic cyclodol abolished rigidity.

    In plain wordsIn rats with DSIP-induced stiffness, the drug cyclodol removed the stiffness.

    Peptide
    Delta sleep-inducing peptide (DSIP)
    Outcome
    DecreaseRigidity after cyclodol
    Study

    ratn: not reported in source

    intracerebral microinjection
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    The systemically cyclodol administration resulted in abolishment of rigidity and increase in locomotor activity.
    1 context sentence
    Summary · context
    Bilateral microinjection of delta-sleep-inducing peptide (DSIP) (10.0 nmol) into the substantia nigra provoked hypokinesia and rigidity in rats

    In this study, Delta sleep-inducing peptide (DSIP) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Delta sleep-inducing peptide (DSIP).

  2. 06AnimalNot a test of Delta sleep-inducing peptide (DSIP) aloneAnimal study (in vivo)Efficacy outcome

    In rats with DSIP-induced parkinsonism, systemic cyclodol increased locomotor activity.

    In plain wordsIn rats with DSIP-induced stiffness, the drug cyclodol increased movement.

    Peptide
    Delta sleep-inducing peptide (DSIP)
    Outcome
    IncreaseLocomotor activity after cyclodol
    Study

    ratn: not reported in source

    intracerebral microinjection
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    The systemically cyclodol administration resulted in abolishment of rigidity and increase in locomotor activity.
    1 context sentence
    Summary · context
    Bilateral microinjection of delta-sleep-inducing peptide (DSIP) (10.0 nmol) into the substantia nigra provoked hypokinesia and rigidity in rats

    In this study, Delta sleep-inducing peptide (DSIP) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Delta sleep-inducing peptide (DSIP).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 17:28 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.